TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31

Tonix Pharmaceuticals Holding Corp.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$5.73−0.31 (-5.13%)

Close on Oct 19, 2026

Market cap: $95.32M
P/E (TTM): –
Dividend yield: –

SEC filings

40 of Tonix Pharmaceuticals's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Oct 15, 2026	Oct 15, 2026	SEC EDGAR
Current report	8-K	Oct 1, 2026	Oct 2, 2026	SEC EDGAR
Current report	8-K	Sep 22, 2026	Sep 22, 2026	SEC EDGAR
Current report	8-K	Sep 8, 2026	Sep 8, 2026	SEC EDGAR
Current report	8-K	Aug 18, 2026	Aug 18, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 10, 2026	SEC EDGAR
Current report	8-K	Aug 10, 2026	Aug 10, 2026	SEC EDGAR
Current report	8-K	Aug 3, 2026	Aug 3, 2026	SEC EDGAR
Current report	8-K	Jul 20, 2026	Jul 21, 2026	SEC EDGAR
Current report	8-K	Jul 13, 2026	Jul 13, 2026	SEC EDGAR
Current report	8-K	Jun 29, 2026	Jun 29, 2026	SEC EDGAR
Current report	8-K	Jun 8, 2026	Jun 8, 2026	SEC EDGAR
Current report	8-K	May 27, 2026	May 27, 2026	SEC EDGAR
Current report	8-K	May 15, 2026	May 15, 2026	SEC EDGAR
Current report	8-K	May 11, 2026	May 11, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 11, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	May 6, 2026	May 6, 2026	SEC EDGAR
Current report	8-K	May 1, 2026	May 1, 2026	SEC EDGAR
Current report	8-K	Apr 29, 2026	Apr 29, 2026	SEC EDGAR
Current report	8-K	Apr 21, 2026	Apr 23, 2026	SEC EDGAR
Current report	8-K	Mar 30, 2026	Mar 31, 2026	SEC EDGAR
Proxy statement	DEF 14A	May 7, 2026	Mar 30, 2026	SEC EDGAR
Current report	8-K	Mar 26, 2026	Mar 26, 2026	SEC EDGAR
Current report	8-K	Mar 16, 2026	Mar 18, 2026	SEC EDGAR
Current report	8-K	Mar 12, 2026	Mar 13, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 12, 2026	SEC EDGAR
Current report	8-K	Mar 10, 2026	Mar 10, 2026	SEC EDGAR
Current report	8-K	Mar 3, 2026	Mar 3, 2026	SEC EDGAR
Current report	8-K	Feb 3, 2026	Feb 3, 2026	SEC EDGAR
Current report	8-K	Dec 29, 2025	Dec 29, 2025	SEC EDGAR
Current report	8-K	Dec 29, 2025	Dec 29, 2025	SEC EDGAR
Current report	8-K	Dec 16, 2025	Dec 16, 2025	SEC EDGAR
Current report	8-K	Dec 9, 2025	Dec 9, 2025	SEC EDGAR
Current report	8-K	Nov 24, 2025	Nov 24, 2025	SEC EDGAR
Current report	8-K	Nov 21, 2025	Nov 21, 2025	SEC EDGAR
Current report	8-K	Nov 18, 2025	Nov 18, 2025	SEC EDGAR
Current report	8-K	Nov 17, 2025	Nov 17, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 10, 2025	SEC EDGAR
Current report	8-K	Nov 10, 2025	Nov 10, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Tonix Pharmaceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-100 reverse split on Mar 18, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is TNXP.

Revenue growth196.0% · median -13.3%

Gross margin83.8% · median 87.1%

Operating margin-568.4% · median -131.4%

Net margin-548.6% · median -147.4%

Company	Revenue	Growth
AYTU	$57.57M	-13.3%
OCUL	$52.05M	-8.1%
LXRX	$41.47M	-29.0%
CPIX	$31.27M	-1.1%
TNXP	$29.10M	+196.0%
STOK	$27.59M	-86.2%

Company

Next earnings (est.): Oct 26, 2026, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 142
Held by institutions: 54.6%
Auditor: EisnerAmper LLP
SEC CIK: 1430306

Advertisement
300 × 250